Accelerating Drug Discovery for FTD

Through this program, AFTD, in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF), seeks to advance and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD. Drug targets in the areas of inflammation and proteostasis are of particular interest.

Current funding priorities for this program include:

  • Lead optimization of novel disease-modifying compounds (e.g., medicinal chemistry refinement, in vitro ADME)
  • In vivo testing of novel lead compounds, biologics, virus-like particle-based vaccines or repurposed drug candidates in relevant animal models for pharmacokinetics, doserange finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.

This program does NOT support:

  • Target identification/validation
  • Assay development
  • High-throughput/high-content screening

Award Details

  • Duration: 1 year, with the possibility of follow-on funding.
  • Average award amount (USD): $100,000 – $150,000.
  • Application of funds: Funding through this program supports approved personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials.
    Funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless pre-approved under special circumstances).

Who can apply?

U.S. and international investigators working at:

  • Academic medical centers and universities; nonprofits
  • Biotechnology companies (existing companies or new spinouts) that demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.

Please review ADDF Funding Policies before applying.

Timeline — 2022 Awards

  • April 2022: RFP posted
  • May 20, 2022: LOIs due
  • July 15, 2022: Invited full proposal due
  • December 2022–January 2023: Notification of awards

Applications are reviewed by ADDF and an external Scientific Review Committee, including members of the AFTD Medical Advisory Council. Applications from biotechnology companies will also be reviewed by ADDF’s Business Advisory Board.


For program-related inquiries, please contact:

For application submission inquiries, please contact:

Visit the ADDF website for additional information.